

Date: 29 May 2025

To

The Secretary BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400 001 Scrip Code: 544293	The Secretary The National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1. G Block Bandra -Kurla Complex, Bandra (East) Mumbai- 400 051 Scrip Symbol : SURAKSHA
---	--

Dear Sir / Ma'am,

Reg: Disclosure under Regulation 30(6) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

Sub: Presentation to be made at the Analyst(s) / Investor(s) Meet/ Conference- Earnings Call

Pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to our intimation dated 24 May 2025 regarding schedule of Analyst(s)/ Investor(s) Meet /Conference i.e Earnings Call on Friday, 30 May 2025 at 03:00 pm (IST), we are hereby enclosing a copy of Investor Presentation on the audited (standalone and consolidated) financial results of the Company for quarter and financial year ended 31 March 2025.

The Investor Presentation will be exhibited at the aforesaid Earnings Call and the same is available on the website of the Company at <https://www.surakshanet.com/pdf/investor/Suraksha-Investor-Presentation-Q4%20-FY-2024-25.pdf>.

Please note that the schedule of the aforesaid Earnings Call is subject to change. The changes might happen due to exigencies on the part of the Company/ Analyst(s)/ Investor(s).

This may please be informed to all the concerned.

For **Suraksha Diagnostic Limited**

Mamta Jain
Company Secretary & Compliance Officer

Encl: As above



Suraksha
Clinic & Diagnostics

Suraksha Diagnostic Limited
Q4 & FY25
Investor Presentation

This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Suraksha Diagnostic Limited** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the Company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the Presentation are not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.




Q4 & FY25 Highlights


Suraksha
Clinic & Diagnostics

Consolidated Financial Performance – FY25


Total Income (₹ million)



EBITDA (₹ million)




PAT (₹ million)




Consolidated Financial Performance - Q4 FY25


Total Income (₹ million)



EBITDA (₹ million)




PAT (₹ million)




Consistent Performance Over the Years


ROE %




ROCE %




Number of Tests (million)




Number of Centres



Revenue / Patient (₹)



EBITDA / Patient(₹)




Expanding Offerings Through Strategic Acquisition



ABOUT FETOMAT

- Incorporated in May 2021, Fetomat Wellness Private Limited ("Fetomat") is a network of fertility and pregnancy care clinics
- Fetomat specializes in pregnancy care, women's ultrasound scans, prenatal diagnosis and advanced therapies
- Fetomat is one of Eastern India's leading centers for fetal and maternal medicine and operated 2 centers as of 31 March, 2024
- For FY24, Fetomat's turnover was ₹ 4.11 crore with an EBITDA of ₹ 0.56 crore

Key Highlights of Strategic Investment



In March 2025, the Board approved a proposal for a strategic investment in Fetomat

Upon deal completion in April 2025, we held 63% stake in Fetomat

This strategic acquisition will help integrate fetal medicine expertise into our existing healthcare framework

The synergies with Fetomat will enhance innovation in fetal medical diagnostics, strengthening our industry position

Profit & Loss Statement (Consolidated)

Particulars (₹ million)	Q4 FY25	Q4 FY24	Y-o-Y	Q3 FY25	Q-o-Q	FY25	FY24	Y-o-Y
Revenue from Operations	650.95	551.88		595.13		2520.93	2187.09	
Other Income	8.17	9.79		5.99		38.46	35.51	
Total Revenue	659.12	561.67	17.35%	601.12	9.65%	2559.39	2222.59	15.15%
Cost of Material Consumed	88.48	65.77		61.03		295.19	272.51	
Employee Benefit Expenses	102.03	89.97		112.87		428.90	400.68	
Other Expenses	260.53	199.46		229.85		962.55	811.88	
Impairment Loss	8.02	2.00		8.82		21.86	1.34	
EBITDA	200.05	204.48	-2.17%	188.55	6.09%	850.88	736.18	15.58%
EBITDA Margin (%)	30.7%	37.1%		31.7%		33.8%	33.7%	
Depreciation	87.29	83.59		88.27		352.98	325.98	
Finance Cost	20.63	20.78		19.82		83.85	87.88	
Profit before Tax & Exceptional Item	92.13	100.11	-7.98%	80.47	14.49%	414.05	322.31	28.46%
Exceptional Item	0.00	7.79		0.00		0.00	7.79	
Profit before Tax	92.13	92.32	-0.22%	80.47	14.49%	414.05	314.53	31.64%
Profit before Tax (%)	14.2%	18.1%		13.5%		16.4%	14.7%	
Tax	20.42	29.11		20.62		104.27	83.26	
Profit After Tax	71.71	63.21	13.44%	59.85	19.82%	309.78	231.26	33.95%
PAT Margin (%)	11.0%	11.5%		10.1%		12.3%	10.6%	
EPS	1.42	1.22		1.18		5.97	4.43	

Balance Sheet (Consolidated)

Particulars (₹ million)	FY25	FY24
Property, plant and equipment	1,471.37	1,350.50
Capital work-in-progress	100.99	13.13
Right-of-use assets	742.90	754.09
Other intangible assets	15.00	10.76
Intangible Assets under Development	4.93	
Financial assets		
Investments	10.00	
Other financial assets	426.91	84.49
Non-current tax assets (net)	16.28	18.31
Other non-current assets	75.33	46.27
Total non-current assets	2,863.71	2,277.56
Inventories	80.49	66.78
Financial assets		
Trade receivables	138.12	88.75
Cash and cash equivalents	22.47	25.20
Bank balances other than cash and cash equivalents	178.59	525.03
Other financial assets	25.30	-
Other current assets	26.56	18.73
Total current assets	471.53	724.49
Total Assets	3,335.24	3,002.05

Particulars (₹ million)	FY25	FY24
Equity share capital	104.16	69.00
Instruments entirely equity in nature	-	16.29
Other equity	2,008.24	1,708.80
Equity attributable to owners of the parent	2,112.40	1,794.08
Non Controlling interest	(10.09)	-2.62
Total equity	2,102.31	1,791.46
Financial liabilities		
Borrowings	28.75	51.83
Lease liabilities	712.28	703.07
Provisions	10.22	7.71
Deferred tax liabilities (net)	54.51	53.86
Total non-current liabilities	805.76	816.47
Financial liabilities		
Borrowings	29.50	34.54
Lease liabilities	118.38	115.33
Trade payables		
Total outstanding dues of micro enterprises and small enterprises	19.67	32.26
Total outstanding dues other than above micro enterprises and small enterprises	116.76	111.66
Other financial liabilities	107.72	77.68
Other current liabilities	33.80	17.46
Provisions	1.25	-
Current tax liabilities (net)	0.08	5.19
Total current liabilities	427.17	394.12
Total equity and liabilities	3,335.24	3,002.05

Cash Flow Statement (Consolidated)

Particulars (₹ million)	FY25	FY24
Cash flow from operating activities		
Profit before tax	414.05	314.52
Adjustments for:		
Depreciation and amortisation expenses	352.98	325.98
Finance costs	83.85	87.88
Interest on loans, deposits and IT refund	-32.45	-32.20
Unwinding of security deposit	-3.34	-2.97
Exceptional items	0.00	7.79
Loss on sale of property, plant and equipment	2.56	21.45
Provision for credit allowances on receivables and deposits	21.86	1.342
Security deposits written off	0.67	-
Bad debts written off	2.68	4.02
Share based payment expenses	2.11	-
Liabilities/ provisions no longer required written back	-2.30	-
Operating profit before working capital changes	842.67	727.82
Changes in operating assets and liabilities		
Adjustments for (increase) / decrease in operating assets		
Trade receivables	-72.12	-47.31
Inventories	-13.71	-5.16
Other financial assets	-30.94	5.29
Other assets	-7.82	2.97
Adjustments for increase / (decrease) in operating liabilities		
Trade payables	-5.19	3.54
Other non-current liabilities	0.00	0
Other liabilities	16.34	5.06

Particulars (₹ million)	FY25	FY24
Other financial liabilities	9.15	-1.77
Provisions	1.04	0.50
Cash generated from operations	739.41	690.92
Income tax paid (net)	-105.82	-86.10
Net cash flows generated from operating activities	633.59	604.81
Cash flows from investing activities		
Purchase of property, plant & equipment, other intangible assets and intangible asset under development (including capital work-in-progress, capital advances and capital creditors)	-420.24	-454.72
Proceeds from sale of property, plant & equipment	1.41	25.52
Net Redemption/(Investments) in deposits with banks	-2.60	47.36
Investment in Company	-10.00	0
Interest received on bank deposits	35.59	31.90
Net cash flows used in investing activities	-395.84	-349.95
Cash flow from financing activities		
Contribution from non-controlling interests	1.00	7.03
Proceeds of borrowings	0.00	5
Repayment of borrowings	-28.11	-58.69
Payment of lease liabilities	-207.00	-195.55
Finance cost paid	-6.37	-9.08
Net cash flows used in financing activities	-240.48	-251.29
Net increase in cash and cash equivalents	-2.73	3.57
Cash and cash equivalents at the beginning of the year	25.20	21.6
Cash and cash equivalents at the end of the year	22.47	25.2

KPIs for FY25

Particulars	Units	FY25	Particulars	Units	FY25	Particulars	Units	FY25
Number of tests per patient [^]	Unit	5.52	Number of tests performed	Unit in million	6.69	Revenue from operations	(₹ in million)	2,520.93
Revenue generated from East India	%	100	Number of Small centres	Unit	26	Restated profit for the year	(₹ in million)	309.78
B2C revenues	%	93.12	Number of Medium centres	Unit	11	EBITDA	(₹ in million)	850.88
B2B revenues	%	6.88	Number of Large centres	Unit	14	EBITDA Margin	%	33.75
Revenue from radiology	%	45.22	Number of Private public partnerships	Unit	4	Return on Equity	%	16.29
Revenue from pathology	%	50.81	Customer touch points			Return on Capital Employed	%	23.30
Revenue from Doctor Consultancy	%	3.97	<ul style="list-style-type: none"> Number of Centres Collection Centres Company Owned Collection Centres 	Unit	55	Net debt/equity	-	0.33
Number of Centres	Unit	55	Total Touch points	Unit	230	Average revenue per patient	(₹)	2,118
Number of Laboratories	Unit	9	Number of doctors (Radiologist & Pathologist)	Unit	313	Average revenue per centre	(₹ in million)	45.84
Number of NABL accredited labs	Unit	4	Number of CT machines	Unit	26	EBITDA per patient	(₹)	715
Number of patients served	Unit in million	1.19	Number of MRI machines	Unit	14	Return on Net Worth	%	16.29
Number of patients served per centre	Unit	23,333				Net asset value per Equity Share (Basic & Diluted)	(₹)	40.56



Company Overview

Suraksha
Clinic & Diagnostics

Business at a Glance

as of 31 March, 2025

9

Labs

1.19 million

**Patients Served
(FY25)**

6.69 million

**Tests Performed
(FY25)**

₹ 2,118

**Revenue per patient
(FY25)**

55

Diagnostic Centres

313

Doctors

26

CT Machines

₹ 715

**EBITDA per patient
(FY25)**

171

Collection Centres

4

NABL accredited labs

14


MRI Machines

₹ 280 million

**Revenue per lab
(FY25)**


Note: National Accreditation Board for Testing and Calibration Laboratories (NABL)

Evolution to the Largest Integrated Diagnostic Chain in East India




Deeply Entrenched in the Vital Geography of West Bengal

- 4th most populous state in India
- Fragmented market with low penetration of chained diagnostic centers
- Accounted for 95.5% of FY24 Revenue from operations




Hub & Spoke Operating Model




Note: 1) as of 31 March 2025

.....with Demonstrated Success



Demonstrated success in Kolkata region with significant potential for future growth²




Hub centres
Offers pathology tests, basic & advanced radiology tests


Spoke centres
Offers pathology tests, basic and intermediate radiology tests

Well-established Operational Network - Greater Economies of Scale

Report Flow




Patients Flow



Well Equipped Clinical Infrastructure



Customer Convenience through Value Added Services



More convenience through online test bookings, consultations and digital test results

Customer Centric Approach

Value Added Services enhancing customer experience and convenience

Home Collection

Allows samples to be collected from the consumers' locations, such as their homes or offices

SMS Alerts

Customers receive an SMS to download the report through email or web portal

Polyclinic Chambers

Polyclinic chambers hosting doctors providing out-patient consultation

Online Bookings

Customers can book appointments and access test reports online

Supported by IT Infrastructure

LIMS

Laboratory Information Management System

RIS

Fully integrated Radiology Information Systems

PACS

Picture Archive and Communication Systems

ERP

Enterprise Resource Planning



Streamline operations



Reduce margin of error



Maintain the TAT



Customer convenience

Experienced Board of Directors



Dr. Somnath Chatterjee

Chairman & Joint Managing Director

- Associated with Suraksha since incorporation; 32+ years of experience in medical and diagnostics business
- Holds bachelor's degree in medicine and surgery from University of Calcutta and is registered with West Bengal Medical Council



Mr. Satish Kumar Verma

Non-Executive, Non-Independent Director

- 40+ years of experience in management
- Holds a bachelor's degree in mechanical engineering and post-graduate diploma in engineering from Punjab University



Mr. Pradip Kumar Dutta

Independent Director

- Several years of work experience. Currently, an advisor to board at Simyog Technology
- Holds B.Tech degree in electronics & electrical communication engineering from IIT, Kharagpur; a MS degree and doctorate in philosophy from the University of Maryland



Ms. Ishani Ray

Independent Director

- 27+ years of experience in finance
- Holds bachelor's degree and master's degree in commerce from the University of Calcutta; she is an associate of the Institute of Chartered Accountants of India



Ritu Mittal

Joint Managing Director & Chief Executive Officer

- Associated with Suraksha since incorporation; 28+ years of experience in the medical and diagnostics business
- Cleared the examination for a bachelor's degree in commerce from the University of Calcutta



Mr. Arun Sadhanandham

Non-Executive, Non-Independent (Nominee) Director

- Nominee of OrbiMed Asia II Mauritius Limited; 13+ years of work experience
- Holds bachelor's degree of engineering from Anna University, Chennai and post graduate diploma in management from IIM, Bengaluru



Mr. Siddhartha Roy

Independent Director

- 39+ years of experience
- Holds bachelor's degree in law from Calcutta University, and also a member of the Institute of Company Secretaries of India



Mr. Dharam Chand Dharewa

Independent Director

- 30+ years of experience
- Holds bachelor's degree in commerce from G.D. Birla Mahavidyalaya, and is practicing chartered accountant since 1987

Dynamic and Diverse Management Team to Deliver the Next Phase of Growth



Ravindra K S

Group Chief Financial Officer

Professional with over 20 years of extensive experience in the finance sector including the role of Group CFO at Medica Hospitals Group, Group Finance Controller at Narayana Hrudayalaya Limited and Group Manager-Finance at Aditya Birla Nuvo Limited

He has a Bachelor's in Commerce from Kuvempu University and is a member of the Institute of Chartered Accountants of India



Mamta Jain

Company Secretary & Compliance Officer

9+ years of experience including with VISA International Limited and Dollar Industries Limited. Holds bachelor's degree in commerce from University of Calcutta, associate member of ICSI, member of the ICWAI and diploma in business administration from Symbiosis Centre for Distance Learning



Balgopal Jhunjhunwala

Regional Business Head

15+ years of experience

Holds bachelor's degree in commerce from University of Calcutta



Niren Kaul

Chief Sales Officer

22+ years of experience, including with Bharti Hexacom Limited and Bharti Infratel Limited. Holds bachelor's degree in electrical engineering from Pandit Ravishankar Shukla University, Raipur and master's degree in business administration from University of Pune



Sangeeta Chakraborty

General Manager, Operations

26+ years of experience

She holds a Bachelor's degree in Arts from the University of Calcutta. She previously worked in the healthcare industry, managing inventory operations and contributing to process efficiency and supply chain coordination



Ajeet Kumar Yadav

GM Supply Chain Management

20+ years of experience included with Aster DM Healthcare
Holds bachelor's degree in commerce from University of Calcutta and PG in Business Management from ICFAI University Tripura and pursuing Master's degree in Production and Operation Management from Amity University for Distance Learning



Strategy and Outlook

Suraksha
Clinic & Diagnostics

Leveraging Strengths to Drive Competitive Advantage



- 01 **Largest diagnostic chain** with a **dominant position in Eastern India**; well-positioned to benefit from the high-growth opportunity for organized diagnostic chains in the fragmented markets in Eastern and North-Eastern India
- 02 **Integrated diagnostics** provider with one-stop solution offering pathology & radiology testing, and **medical consultation services**
- 03 Technologically **advanced clinical infrastructure** and trained personnel ensuring high quality and reliable diagnostic services
- 04 **High brand recall** and commitment to superior quality, driving high individual consumer business share and **customer retention**
- 05 **Track record of profitability** and consistent financial performance
- 06 Management team with **robust industry experience**

Key Differentiating Factors

Polyclinic

132

Chambers¹



1,000+

Doctors¹


Omnichannel medical consultation services via online and offline modes through diagnostic centres which house the polyclinic chambers

Model of integrated pathology, radiology and medical consultation services offers significant barriers to entry

Comprehensive suite of 2,300+ diagnostic tests¹



Diversified in terms of revenue from services



Strategies to Drive Future Growth



01 Strengthen position in core geography

02 Expand in adjacent geographies of Eastern and North-Eastern India

03 Supplement organic growth with selective acquisitions

04 Leverage technology to elevate customer experience

05 Increase share of medical consultation services at diagnostic centres

06 Engage in Business-to-Business ("B2B") and corporate partnerships

Targeting Organic and Inorganic Opportunities in Core and Adjacent Markets

Consolidate leading position in the core geography by



Open additional diagnostic centres and increase franchisee partnerships with local entrepreneurs



Enhance the laboratory capacity and test menu by adding latest technologies



Increase home collection services



Set up more hub centres to form new clusters, and spoke centres in existing clusters

Expand in adjacent geographies of Eastern and North-Eastern India



Identify key locations in Eastern and North-Eastern India



Replicate the
(a) 'hub and spoke' model to unlock economies of scale
(b) polyclinic model to drive higher number of patient footfalls



Build spoke centers around the existing hub centers in Bihar, Guwahati and Meghalaya

Leverage technology to elevate customer experience



Create a convenient one-stop solution through integration of digital technology, artificial intelligence and machine learning



Increase the touch points and engagement with customers through digital and technological initiatives

Increase share of medical consultation services at diagnostic centres



Set up more polyclinics in the existing diagnostic centres, and increase the number and specialties of doctors associated



Achieve higher footfalls, tests per patient, and average revenue per patient

Supplement organic growth with selective acquisitions



Selective acquisitions of and/or strategic partnerships with local diagnostic centres across Eastern and North-Eastern India



Factors while evaluating acquisition targets

- Brand recognition
- Customer base
- Technical capability and resources

Engage in Business-to-business ("B2B") and corporate partnerships



Enhance revenue from the B2B segment to further diversify revenue mix and increase customer base & brand penetration



Actively seek institutional customers through referrals or internal lead-generation




Industry Overview


Suraksha
Clinic & Diagnostics

Industry: Poised for High Growth; Shifting Towards Organized Market



Diagnostic market expected to grow at 10-12% CAGR between FY24 & FY28



Organized players gaining market share from standalone labs at a steady rate



Radiology expected to grow at a relatively faster pace



Segment wise break-up of diagnostics market (FY24E)

Pathology Market (INR bn)


Radiology Market (INR bn)

Source: CRISIL Report

Note: 1) For FY20 & FY24E, Multiregional Chains account for 35-40% & 34-38% respectively of the overall Diagnostic Chains; For FY20 & FY24E, Regional Chains account for 60-65% & 62-66% respectively of the overall Diagnostic Chains


Eastern India - An “Underserved” Market with Premium Pricing

Disparity in access to accredited testing services in Eastern⁽¹⁾ India relative to population needs




NABL labs per mn population (Feb 2024)

Region has the lowest number of NABH accredited hospitals



Region wise NABH accredited hospitals

East India⁽¹⁾ market also offers premium pricing for diagnostic tests






Region-wise average diagnostic test expenditure⁽²⁾ (INR)

East India⁽¹⁾ has the highest share of population, yet the lowest share of Indian diagnostics market

East India⁽¹⁾ diagnostics market is expected to grow at 10.5-12.5% CAGR between FY24 and FY28

West Bengal diagnostics market is expected to grow at 10.5-12.5% CAGR between FY24 and FY28



Source: CRISIL Report

Note: 1) East including Northeast region is defined as: Bihar, Jharkhand, Odisha, West Bengal, Chhattisgarh; Sikkim, Arunachal Pradesh, Assam, Tripura, Mizoram, Nagaland, Manipur, Meghalaya; 2) For non-hospitalization

Key Awards & Recognition



Best quality in service delivery⁽¹⁾



Best customer service in healthcare⁽¹⁾



Business leader of the year⁽²⁾



Awards & certificate of excellence⁽³⁾



Outstanding diagnostic chain of eastern India⁽⁴⁾



Certificate of excellence in exemplary trust & commitment towards diagnostic services⁽⁵⁾



Thank You

For further information, please contact:

Company :

Suraksha
Clinic & Diagnostics

Suraksha Diagnostic Limited

CIN: L85110WB2005PLC102265

Email: investors@surakshanet.com

Investor Relations Advisors :

MUFG

MUFG Intime India Private Limited

A part of MUFG Corporate Markets, a division of
MUFG Pension & Market Services

Mr. Ashish Tendulkar

ashish.tendulkar@in.mpms.mufg.com

Ms. Pooja Swami

pooja.swami@in.mpms.mufg.com

Meeting Request Link – [Click Here](#)